Current Pharmaceutical Design

9.6k papers and 277.1k indexed citations i.

About

The 9.6k papers published in Current Pharmaceutical Design in the last decades have received a total of 277.1k indexed citations. Papers published in Current Pharmaceutical Design usually cover Molecular Biology (3.1k papers), Oncology (882 papers) and Pharmacology (776 papers) specifically the topics of Computational Drug Discovery Methods (429 papers), Nanoparticle-Based Drug Delivery (332 papers) and RNA Interference and Gene Delivery (255 papers). The most active scholars publishing in Current Pharmaceutical Design are Amirhossein Sahebkar, Emilio Jirillo, Claudiu T. Supuran, Mohammad Amjad Kamal and Sho‐ichi Yamagishi.

In The Last Decade

Fields of papers published in Current Pharmaceutical Design

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Current Pharmaceutical Design. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Current Pharmaceutical Design

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Current Pharmaceutical Design. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Current Pharmaceutical Design with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025